Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anaveon

- PMLiVE

Gilead and Arcus complete closing of ten-year immunotherapy partnership

Deal emphasises Gilead's focus on immuno-oncology

- PMLiVE

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Deal focuses on T cell receptor therapies

- PMLiVE

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC

- PMLiVE

Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

Solidifies immunotherapy drug's dominance in the setting

AstraZeneca AZ

AZ’s Imfinzi scores orphan drug status in liver cancer

Company is looking to gain approval in the first-line advanced setting

- PMLiVE

NantKwest rockets on promising pancreatic cancer data

One patient demonstrated a complete response following treatment

- PMLiVE

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Acquisition bolsters immuno-oncology pipeline

- PMLiVE

Merck’s Keytruda significantly extends life in some prostate cancer patients

Pivotal study identifies group of 'super responders'

- PMLiVE

European biotech: a new generation of leaders emerges

Three companies that are on the rise in biotech

- PMLiVE

France’s Innate Pharma eyes $100m Nasdaq IPO

Would help fund development of antibody-based immunotherapies

- PMLiVE

Encouraging signs in biomarker R&D

The cancer immunotherapy firms ramping-up biomarker R&D

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links